Balanced product information
Evidence, limitations and safety — in one consistent format.
This page separates authorised uses from investigational or reported uses. It does not provide personal medical advice or dosing instructions.
Product name
BPC-157 and TB-500 peptide combination
Catalogue label details describe what is displayed; they do not independently verify composition, quality, batch release or UK marketing authorisation.
What is it?
BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence described in gastric proteins. TB-500 is a name used for synthetic material related to thymosin beta-4 signalling.
The combined 12mg/28mg injection presentation is not an established medicinal product and lacks reliable human characterisation.
Intended / recognised uses
Authorised / recognised uses
- There are no authorised medical uses for BPC-157, TB-500 or this combination in the UK.
Reported / investigational uses
- They are promoted online for injury healing, inflammation or recovery, but most supporting work is laboratory or animal research.
- Human efficacy, appropriate exposure and long-term outcomes remain unestablished.
How it works
Preclinical reports propose effects on cell migration, blood-vessel signalling, nitric-oxide pathways and tissue repair.
Proposed mechanisms do not establish a clinical benefit or safe human formulation, particularly for a combined injection.
Potential benefits / effects
- No clinically established benefit has been demonstrated for this exact combination.
- Animal or laboratory findings cannot reliably predict healing, pain reduction, performance or recovery in people.
Potential benefit is not a guarantee of benefit for any individual.
Risks & warnings
- Short- and long-term human safety are insufficiently characterised.
- Potential risks include immune reactions, injection-related infection, contamination, incorrect concentration and unpredictable systemic effects.
- Pathways involving blood-vessel formation and tissue growth create theoretical concerns that have not been resolved by adequate human studies.
Possible side effects
Frequency not established
- There are no reliable data defining common side effects for the combination.
- Injection-site pain, redness, swelling, infection, headache, nausea or allergic reactions are possible but frequencies are unknown.
Serious or urgent concerns
- Breathing difficulty, facial swelling, high fever, spreading redness, severe pain or any unexpected systemic reaction requires urgent care.
- Unknown adverse effects remain a major limitation.
Who should not use it / precautions
- These peptides should not be used outside an appropriately authorised research setting.
- Pregnancy, breastfeeding, childhood, active or previous cancer, immune disorders, bleeding disorders, planned surgery and serious liver or kidney disease increase uncertainty and concern.
- Competitive athletes should check anti-doping rules: BPC-157 and thymosin-beta-4 derivatives including TB-500 are prohibited by WADA.
Interactions
- No reliable human interaction studies exist for this combination.
- Possible interactions with anticoagulants, immune-modifying medicines, cancer therapies or other peptides are unknown rather than proven absent.
- All medicines and supplements should be disclosed to a qualified clinician.
Regulatory / legal status
- BPC-157 and TB-500 are not UK-authorised medicines.
- The 40mg HELIX combination has not been verified as an authorised medicinal product and should not be described as approved or clinically validated.
- Both substances are relevant to current anti-doping restrictions.
Monitoring / professional supervision
- There is no validated clinical monitoring protocol that makes unsupervised use safe.
- A legitimate research study would require eligibility screening, authenticated material, sterility and quality controls, protocol-defined safety tests and adverse-event reporting.
- Routine self-monitoring cannot resolve unknown composition or long-term risk.
Evidence & sources
Sources are selected for regulatory status, recognised uses and material safety information. They do not validate the HELIX-labelled presentation.
- World Anti-Doping Agency — Prohibited List
- US FDA — Bulk substances that may present significant compounding safety risks
- ClinicalTrials.gov — BPC-157 study record NCT02637284
- UK government — Image and performance enhancing drugs guidance
Sources accessed and content reviewed 12 September 2026. Regulatory status can change; consult the current official record.
Information disclaimer
HELIX — FOR INFORMATION ONLY. NOT FOR SALE.
The products displayed on this website are presented strictly for informational and educational purposes, helping visitors understand their descriptions, features and specifications. No products are offered for sale through this website, and no product orders or payments are accepted through this platform.
The information on this website does not constitute medical advice, a prescription or a recommendation to use any product. Displaying a product does not establish its regulatory approval, safety or suitability for an individual. Please consult an appropriately qualified healthcare professional for personal medical advice.
For a UK-facing website, this disclaimer does not by itself establish legal compliance. Public advertising of prescription-only medicines and advertising of unlicensed medicines are subject to legal restrictions; the catalogue, wording and presentation require appropriate regulatory review.
Licensed-provider information
Where permitted by applicable law, HELIX may display contact details for independent third-party providers whose registration details have been checked against an appropriate official register. Visitors may contact a listed provider directly to enquire about lawful availability and eligibility requirements.
Any supply is subject to the provider’s assessment, applicable regulations, and verification of all required documentation, which may include a valid prescription, professional licence, identification or other authorisation. A referral does not guarantee availability, eligibility or supply.
Registration status can change. Review the provider's regulator, registration number, official-register record and last-checked date, then verify the current status independently before engaging.